Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2023)
Top biotech stocks in 2023 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology

Overview Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends Ownership

Ticker	Company	Country	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
HRMY	HARMONY BIOSCIENCES HOLDINGS INC	United States	$1.95B	59,620,731	62.67%	37.33%	Net Selling	Net Selling
BNTX	BIONTECH SE	Germany	$30.02B	240,993,998	16.46%	0.00%
DVAX	DYNAVAX TECHNOLOGIES CORP	United States	$1.25B	127,686,631	69.09%	30.91%	Net Selling	Net Selling
CPRX	CATALYST PHARMACEUTICALS INC	United States	$1.75B	105,654,395	79.61%	17.05%	Net Selling	Net Buying
OCUP	OCUPHIRE PHARMA INC	United States	$78.55M	20,947,830	1.03%	98.97%	Net Buying
KNSA	KINIKSA PHARMACEUTICALS LTD	Bermuda	$750.54M	69,753,123	43.41%	9.96%	Net Selling	Net Selling
TBPH	THERAVANCE BIOPHARMA INC	Cayman Islands	$682.08M	62,864,474	66.21%	33.79%	Net Selling	Net Selling
SELB	SELECTA BIOSCIENCES INC	United States	$213.11M	153,318,915	34.92%	38.28%	Net Buying	Net Selling
VIR	VIR BIOTECHNOLOGY INC	United States	$3.11B	133,531,379	61.03%	38.97%	Net Selling	Net Selling
UTHR	UNITED THERAPEUTICS CORP	United States	$10.37B	46,301,656	87.61%	12.39%	Net Selling	Net Selling
CMRX	CHIMERIX INC	United States	$111.22M	88,273,567	59.14%	31.08%	Net Buying	Net Buying
IMTX	IMMATICS NV	Germany	$529.03M	76,670,699	44.41%	0.00%
CDMO	AVID BIOSERVICES INC	United States	$1.17B	62,547,056	92.37%	7.63%	Net Selling	Net Selling
REGN	REGENERON PHARMACEUTICALS INC	United States	$89.83B	109,325,532	69.99%	30.01%	Net Selling	Net Selling
MRNA	MODERNA INC	United States	$59.33B	386,339,594	64.14%	22.31%	Net Selling	Net Selling
SIGA	SIGA TECHNOLOGIES INC	United States	$415.16M	72,201,169	33.41%	66.59%	Net Selling
ZYME	ZYMEWORKS INC	Canada	$578.93M	64,041,287	60.52%	39.48%	Net Buying	Net Buying
MOLN	MOLECULAR PARTNERS AG	Switzerland	$217.64M	36,044,706	2.55%	0.00%
VRTX	VERTEX PHARMACEUTICALS INC	United States	$81.00B	257,091,441	91.64%	1.52%	Net Selling	Net Selling
GMAB	GENMAB A	Denmark	$24.91B	65,961,573	69.29%	0.00%
MRVI	MARAVAI LIFESCIENCES HOLDINGS INC	United States	$3.51B	250,879,331	33.93%	66.07%	Net Selling	Net Selling
ABCL	ABCELLERA BIOLOGICS INC	Canada	$2.17B	287,686,199	44.27%	45.83%	Net Buying	Net Buying
VACC	VACCITECH PLC	United Kingdom	$85.88M	38,338,764	26.68%	55.14%	Net Selling	Net Selling
GNFT	GENFIT SA	France	$204.24M	49,815,489	4.33%	0.00%
NBIX	NEUROCRINE BIOSCIENCES INC	United States	$9.78B	96,587,911	69.08%	30.92%	Net Selling	Net Selling
CGEM	CULLINAN ONCOLOGY INC	United States	$402.32M	39,327,298	49.04%	50.96%	Net Buying	Net Selling
APVO	APTEVO THERAPEUTICS INC	United States	$14.73M	7,239,471	13.31%	50.90%
RPTX	REPARE THERAPEUTICS INC	Canada	$414.05M	42,077,896	59.26%	40.74%	Net Selling
ITOS	ITEOS THERAPEUTICS INC	United States	$486.15M	35,720,401	61.88%	38.12%	Net Selling	Net Buying
ARCT	ARCTURUS THERAPEUTICS HOLDINGS INC	United States	$636.53M	26,555,483	85.25%	14.62%	Net Buying	Net Selling
VCYT	VERACYTE INC	United States	$1.61B	72,149,636	64.34%	35.66%	Net Selling	Net Selling
ACET	ADICET BIO INC	United States	$247.42M	42,954,975	73.19%	26.81%	Net Selling	Net Selling
XENE	XENON PHARMACEUTICALS INC	Canada	$2.26B	63,037,991	95.84%	4.03%	Net Selling	Net Buying
ICPT	INTERCEPT PHARMACEUTICALS INC	United States	$559.63M	41,670,120	49.86%	50.14%	Net Selling	Net Selling
PULM	PULMATRIX INC	United States	$10.66M	3,652,285	7.87%	92.13%
PGEN	PRECIGEN INC	United States	$267.33M	252,194,713	16.76%	70.39%	Net Buying	Net Buying
MORF	MORPHIC HOLDING INC	United States	$1.49B	39,534,138	57.76%	42.24%	Net Buying	Net Buying
ZLAB	ZAI LAB LTD	China	$3.26B	979,087,430	5.94%	1.96%	Net Buying	Net Buying
IDYA	IDEAYA BIOSCIENCES INC	United States	$664.36M	48,387,222	86.10%	13.90%
VBLT	VASCULAR BIOGENICS LTD	Israel	$11.72M	69,750,117	3.54%	8.74%
DBVT	DBV TECHNOLOGIES SA	France	$317.81M	94,025,441	57.15%	15.63%
PPBT	PURPLE BIOTECH LTD	Israel	$33.08M	184,815,092	0.09%	0.00%
ONTX	ONCONOVA THERAPEUTICS INC	United States	$15.33M	20,969,559	7.40%	83.87%	Net Selling	Net Selling
IMRN	IMMURON LTD	Australia	$10.68M	227,798,346	0.04%	0.00%
CRNX	CRINETICS PHARMACEUTICALS INC	United States	$865.78M	53,908,865	81.66%	18.34%	Net Selling	Net Selling
XBIO	XENETIC BIOSCIENCES INC	United States	$6.16M	15,166,596	4.58%	26.79%
BLU	BELLUS HEALTH INC	Canada	$911.28M	126,567,121	89.84%	0.00%
LMNL	LIMINAL BIOSCIENCES INC	Canada	$117.96M	31,042,560	0.59%	0.00%
TECH	BIO-TECHNE CORP	United States	$11.67B	157,275,200	95.21%	2.11%	Net Buying	Net Buying
OMER	OMEROS CORP	United States	$292.15M	62,828,765	31.04%	5.93%
SRRK	SCHOLAR ROCK HOLDING CORP	United States	$415.88M	51,985,072	57.25%	42.75%	Net Buying	Net Buying
ALEC	ALECTOR INC	United States	$513.94M	83,027,910	53.96%	46.04%	Net Selling	Net Selling
PTE	POLARITYTE INC	United States	$3.69M	7,323,755	2.16%	97.84%	Net Selling	Net Buying
ALT	ALTIMMUNE INC	United States	$207.96M	49,278,861	42.67%	57.33%	Net Selling	Net Buying
INCY	INCYTE CORP	United States	$16.11B	222,965,018	78.83%	21.17%	Net Selling	Net Buying
BMRN	BIOMARIN PHARMACEUTICAL INC	United States	$18.14B	186,528,784	97.63%	1.50%	Net Selling	Net Selling
SURF	SURFACE ONCOLOGY INC	United States	$42.44M	60,716,873	29.65%	70.35%	Net Selling
SLGL	SOL-GEL TECHNOLOGIES LTD	Israel	$89.74M	23,129,469	24.64%	0.00%
ATXS	ASTRIA THERAPEUTICS INC	United States	$372.22M	27,986,718	62.26%	37.74%	Net Buying
ATRA	ATARA BIOTHERAPEUTICS INC	United States	$278.19M	95,926,711	92.97%	7.03%	Net Selling	Net Selling
CWBR	COHBAR INC	United States	$5.20M	2,906,926	0.94%	99.06%	Net Buying
SILO	SILO PHARMA INC	United States	$6.63M	3,158,797	0.68%	5.03%	Net Buying
ARTL	ARTELO BIOSCIENCES INC	United States	$6.63M	2,855,688	4.10%	29.20%	Net Buying
CORT	CORCEPT THERAPEUTICS INC	United States	$2.34B	107,899,316	30.30%	69.70%	Net Buying	Net Buying
CMMB	CHEMOMAB THERAPEUTICS LTD	Israel	$17.57M	220,996,240	1.50%	7.66%	Net Selling	Net Selling
VYNE	VYNE THERAPEUTICS INC	United States	$10.05M	3,264,272	22.22%	77.78%	Net Buying	Net Buying
NVIV	INVIVO THERAPEUTICS HOLDINGS CORP	United States	$3.03M	2,860,446	0.95%	99.05%
DOMH	DOMINARI HOLDINGS INC	United States	$15.59M	4,840,597	12.87%	78.69%	Net Buying
INVA	INNOVIVA INC	United States	$766.42M	68,126,089	63.59%	36.41%	Net Selling	Net Buying
VNDA	VANDA PHARMACEUTICALS INC	United States	$385.57M	56,785,264	58.91%	41.09%	Net Selling	Net Selling
BEAM	BEAM THERAPEUTICS INC	United States	$2.22B	72,397,631	76.70%	23.30%	Net Selling	Net Selling
TRVI	TREVI THERAPEUTICS INC	United States	$111.08M	60,045,096	19.11%	80.89%	Net Buying	Net Buying
MEIP	MEI PHARMA INC	United States	$30.52M	133,260,865	37.14%	9.31%	Net Buying	Net Buying
LSTA	LISATA THERAPEUTICS INC	United States	$25.95M	7,998,342	0.83%	99.17%	Net Buying	Net Selling
PSTX	POSEIDA THERAPEUTICS INC	United States	$266.50M	86,527,203	49.73%	43.92%	Net Buying	Net Selling
IMMP	IMMUTEP LTD	Australia	$147.72M	879,295,626	0.47%	0.00%
ADMA	ADMA BIOLOGICS INC	United States	$735.34M	222,155,625	68.71%	26.48%	Net Selling	Net Selling
SPRO	SPERO THERAPEUTICS INC	United States	$76.23M	52,571,813	27.05%	61.72%	Net Selling	Net Selling
FBRX	FORTE BIOSCIENCES INC	United States	$21.22M	21,007,069	18.10%	33.47%	Net Buying
ACRS	ACLARIS THERAPEUTICS INC	United States	$539.55M	66,692,964	65.46%	34.54%	Net Selling	Net Selling
PRTA	PROTHENA CORP PUBLIC LTD CO	Ireland	$2.55B	52,564,434	51.02%	48.98%	Net Buying	Net Buying
ACST	ACASTI PHARMA INC	Canada	$20.52M	44,612,831	0.11%	20.34%
PRTC	PURETECH HEALTH PLC	United States	$834.32M	287,796,585	0.48%	0.00%
ABIO	ARCA BIOPHARMA INC	United States	$28.68M	14,410,143	1.80%	98.20%	Net Buying
EPIX	ESSA PHARMA INC	Canada	$130.95M	44,092,374	72.45%	27.55%	Net Buying
JNCE	JOUNCE THERAPEUTICS INC	United States	$96.46M	52,140,277	59.53%	40.47%	Net Buying	Net Buying
FIXX	HOMOLOGY MEDICINES INC	United States	$59.41M	57,678,435	36.59%	20.22%	Net Selling	Net Selling
AUTL	AUTOLUS THERAPEUTICS PLC	United Kingdom	$318.46M	173,074,510	62.34%	0.00%
CGEN	COMPUGEN LTD	Israel	$60.81M	86,624,643	18.70%	0.00%
SAGE	SAGE THERAPEUTICS INC	United States	$2.51B	59,717,608	69.94%	30.06%	Net Buying	Net Buying
IKNA	IKENA ONCOLOGY INC	United States	$125.09M	36,257,493	72.44%	23.38%	Net Buying
RNA	AVIDITY BIOSCIENCES INC	United States	$1.09B	70,807,973	81.46%	18.54%	Net Buying	Net Buying
AEZS	AETERNA ZENTARIS INC	Canada	$12.72M	4,855,876	0.72%	0.00%
CRDF	CARDIFF ONCOLOGY INC	United States	$73.72M	44,677,169	17.24%	34.48%	Net Buying
UPC	UNIVERSE PHARMACEUTICALS INC	China	$12.66M	21,750,000	0.30%	0.00%
AADI	AADI BIOSCIENCE INC	United States	$176.92M	24,436,990	30.68%	69.32%	Net Buying
AFMD	AFFIMED NV	Germany	$111.41M	149,339,335	54.11%	0.00%
EXEL	EXELIXIS INC	United States	$6.29B	324,087,337	86.44%	2.82%	Net Selling	Net Selling
BCYC	BICYCLE THERAPEUTICS PLC	United Kingdom	$638.55M	30,021,071	54.96%	45.04%	Net Selling	Net Selling
LUMO	LUMOS PHARMA INC	United States	$27.21M	8,219,292	17.99%	82.01%	Net Buying	Net Buying

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2023?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Harmony Biosciences Holdings (NASDAQ:HRMY)

Harmony Biosciences Holdings (NASDAQ:HRMY) is the top biotech stock with a Zen Score of 62, which is 37 points higher than the biotech industry average of 25. It passed 20 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -32.89% over the past year, underperforming other biotech stocks by -7 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $60.50, an upside of 85.3% from Harmony Biosciences Holdings's current stock price of $32.65.

Harmony Biosciences Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 50% have issued a Strong Buy rating, 33.33% have issued a Buy, 16.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX) is the second best biotech stock with a Zen Score of 59, which is 34 points higher than the biotech industry average of 25. It passed 19 out of 33 due diligence checks and has strong fundamentals. Dynavax Technologies has seen its stock lose -9.5% over the past year, overperforming other biotech stocks by 17 percentage points.

Dynavax Technologies has an average 1 year price target of $24.33, an upside of 148.04% from Dynavax Technologies's current stock price of $9.81.

Dynavax Technologies stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Dynavax Technologies, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Biontech Se (NASDAQ:BNTX)

Biontech Se (NASDAQ:BNTX) is the third best biotech stock with a Zen Score of 59, which is 34 points higher than the biotech industry average of 25. It passed 22 out of 38 due diligence checks and has strong fundamentals. Biontech Se has seen its stock lose -26.96% over the past year, underperforming other biotech stocks by -1 percentage points.

Biontech Se has an average 1 year price target of $170.89, an upside of 37.18% from Biontech Se's current stock price of $124.57.

Biontech Se stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Biontech Se, 22.22% have issued a Strong Buy rating, 11.11% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 6 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Kineta (NASDAQ:KA)

Kineta (NASDAQ:KA) has an annual dividend yield of 302.42%, which is 262 percentage points higher than the biotech industry average of 40.89%.

Kineta's dividend payout ratio of -88.9% indicates that its high dividend yield might not be sustainable for the long-term.

2. Carisma Therapeutics (NASDAQ:CARM)

Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of 11.66%, which is -29 percentage points lower than the biotech industry average of 40.89%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

3. Siga Technologies (NASDAQ:SIGA)

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 7.83%, which is -33 percentage points lower than the biotech industry average of 40.89%.

Siga Technologies's dividend payout ratio of 97.8% indicates that its high dividend yield might not be sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.18% in the last day, and up 1.75% over the last week. Y Mabs Therapeutics was the among the top gainers in the biotechnology industry, gaining 52.28% yesterday.

Y-mAbs Therapeutics shares are trading higher after the company reported mixed Q4 financial results and filed for a $150 million mixed shelf offering.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ:INVA) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Innoviva has a valuation score of 100, which is 71 points higher than the biotech industry average of 29. It passed 7 out of 7 valuation due diligence checks.

Innoviva's stock has dropped -41.86% in the past year. It has underperformed other stocks in the biotech industry by -16 percentage points.

2. Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics (NASDAQ:VBLT) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Vascular Biogenics has a valuation score of 100, which is 71 points higher than the biotech industry average of 29. It passed 7 out of 7 valuation due diligence checks.

Vascular Biogenics's stock has dropped -90.06% in the past year. It has underperformed other stocks in the biotech industry by -64 percentage points.

3. Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Dynavax Technologies has a valuation score of 86, which is 57 points higher than the biotech industry average of 29. It passed 6 out of 7 valuation due diligence checks.

Dynavax Technologies's stock has dropped -9.5% in the past year. It has overperformed other stocks in the biotech industry by 17 percentage points.

Are biotech stocks a good buy now?

46.42% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 83.24% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 18.64x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.